

Key reporting guidelines and other EQUATOR resources

Iveta Simera

The EQUATOR Network workshop
31 October 2013, WHO, Geneva



EQUATOR Network



Enhancing the **QUALITY** and
Transparency Of health Research



Visit the EQUATOR
[Spanish Website](#)

[Home](#) [Library](#) [Toolkits](#) [Courses & events](#) [News](#) [Blog](#) [About us](#) [Contact](#)

The resource centre for good reporting of health research studies



Library for health research reporting

The Library contains a comprehensive searchable database of reporting guidelines and also links to other resources relevant to research reporting.



Search for reporting guidelines



Visit the library for more resources



Key reporting guidelines

CONSORT	Full Record Checklist Flow Diagram
STROBE	Full Record Checklist
PRISMA	Full Record Checklist Flow Diagram
STARD	Full Record Checklist Flow Diagram
COREQ	Full Record
ENTREQ	Full Record
SQUIRE	Full Record Checklist
CHEERS	Full Record Checklist
CARE	Full Record Checklist
SAMPL	Full Record



Toolkits

The EQUATOR Network works to improve the reliability and value of medical research literature by promoting transparent and accurate reporting of research studies.

Our Toolkits support different user groups, including:

Authors

Information and resources for authors

Editors

EQUATOR highlights

3/10/2013 - OPEN: To overcome failure to publish negative findings

The EU-funded OPEN project (Overcome failure to Publish nEgative fiNdings) brought together key opinion leaders from across Europe to address the issue of publications bias. [Read More](#)

17/09/2013 - EQUATOR Network at the Peer Review Congress 2013 in Chicago

EQUATOR actively participated at the Seventh International Congress on Peer Review and Biomedical Publication, 8-10 September 2013, Chicago, USA. We organised the EQUATOR workshop for editors on reporting of research studies (Saturday 7 September am) and the EQUATOR 5th Annual ... [Read More](#)

10/08/2013 - Declaration of transparency

News

[EQUATOR Network Newsletter October 2013](#)
22/10/2013

[The Checklist Manifesto Meets Clinical Trials](#)
9/10/2013

[Publicly available sources provide insufficient information on patient-relevant outcomes of clinical trials](#)
9/10/2013

[New EASE Science Editors' Handbook published](#)
1/10/2013

[Clinical Trials 2013 – 2014](#)
20/09/2013



[Home](#) > [Library](#) > Reporting guideline

Search for reporting guidelines



Browse for reporting guidelines by selecting one or more of these drop-downs:

Study type

Please select... ▾

and

Clinical area

Please select... ▾

and

Section of report

Please select... ▾

Or search with free text

[Start again](#) | [Help](#)

Displaying 218 reporting guidelines found.

Most recently added records are displayed first.



1

[Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries](#)



2

[The Strengthening the Reporting of Observational Studies in Epidemiology \(STROBE\) Statement: guidelines for reporting observational studies](#)



3

[CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials](#)



Key reporting guidelines

CONSORT	Full Record Checklist Flow Diagram
STROBE	Full Record Checklist
PRISMA	Full Record Checklist Flow Diagram
STARD	Full Record Checklist Flow Diagram
COREQ	Full Record
ENTREQ	Full Record
SQUIRE	Full Record Checklist
CHEERS	Full Record Checklist
CARE	Full Record Checklist
SAMPL	Full Record

Translations


Some reporting guidelines are also available in languages other than English. Find out more in our [Translations section](#).

About the Library

For information about Library scope and content, identification of reporting guidelines and inclusion/exclusion criteria please visit [About the Library](#).

Visit our [Help page](#) for information about searching

CONsolidated Standards Of Reporting Trials



The screenshot shows the CONSORT website homepage. At the top left is the CONSORT logo with a checkmark and the text 'CONSORT TRANSPARENT REPORTING of TRIALS'. To the right are social media icons for RSS and Twitter, a 'Support CONSORT' button, and a search bar with a 'Go' button. A navigation menu below the header includes 'Home', 'CONSORT Statement', 'Extensions', 'About CONSORT', 'Library of Examples', 'Resources', and 'News'. On the left side, there is a red folder icon labeled '+ AllTrials' and a blue button labeled 'Submit Example'. The main content area features a 'Welcome to the CONSORT Statement Website' section with three paragraphs of text. To the right, there is a 'News' section with a sub-heading 'In Memoriam' and a paragraph about Dr. Vincent Kokich, followed by a 'Read more' link. At the bottom right of the page is a photograph of three men standing together at a social event.

CONSORT
TRANSPARENT REPORTING of TRIALS

Home | CONSORT Statement | Extensions | About CONSORT | Library of Examples | Resources | News

+ AllTrials

Please join CONSORT in supporting the All Trials campaign to get all clinical trial results reported.

Reporting Examples

Submit Example

If you find an example of good reporting, login here to submit it to our Library.

Welcome to the CONSORT Statement Website

CONSORT, which stands for Consolidated Standards of Reporting Trials, encompasses various initiatives developed by the CONSORT Group to alleviate the problems arising from inadequate reporting of randomized controlled trials (RCTs).

The main product of CONSORT is the [CONSORT Statement](#), which is an evidence-based, minimum set of recommendations for reporting RCTs. It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, and aiding their critical appraisal and interpretation.

The CONSORT Statement comprises a 25-item [checklist](#) and a [flow diagram](#), along with some brief descriptive text. The checklist items focus on reporting how the trial was designed, analyzed, and interpreted; the flow diagram displays the progress of all participants through the trial.

Considered an evolving document, the CONSORT Statement is subject to periodic changes as new evidence emerges. This website contains the current definitive version of the CONSORT Statement and up-to-date information on extensions.

News

In Memoriam

Dr. Vincent Kokich, Editor-in-Chief of the American Journal of Orthodontics and Dentofacial Orthopedics (AJODO) and strong promoter of CONSORT and PRISMA passes away

[Read more](#)



Reporting randomised trials

- CONSORT Statement first published in 1996, revised 2001, 2010

History:

- Two sets of recommendations for reporting RCTs published in 1994 (SORT Group, Asilomar Group)
- CONSORT meeting in Chicago, 1995

- CONSORT Statement is an evidence-based, minimum set of recommendations for reporting RCTs

It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, and aiding their critical appraisal and interpretation.

2010 Revision of CONSORT

- Revised checklist
- Short paper
(published in 9 journals)
- Revised (and expanded)
explanatory paper (E&E)

OPEN ACCESS freely available online

PLoS MEDICINE

Guidelines and Guidance

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials

Kenneth F. Schulz^{1*}, Douglas G. Altman², David Moher³, for the CONSORT Group⁴

1 Family Health International, Research Triangle Park, North Carolina, United States of America, 2 Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, United Kingdom, 3 Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

Introduction

Randomised controlled trials, when appropriately designed, conducted, and reported, represent the gold standard in evaluating

...submit goal of our work. Moreover, CONSORT can help researchers in designing their trial.

Background to CONSORT

Schulz et al. *Trials* 2010, 11:32
<http://www.trialsjournal.com/content/11/1/32>

RESEARCH

Open Access

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Kenneth F Schulz^{1*}, Douglas G Altman², David Moher³, for the CONSORT Group

BMC Medicine

IMPACT FACTOR 3.99

home | journals A-Z | subject areas | advanced search | authors | reviewers | libraries | about | my BioMed Central

Correspondence

Highly accessed Open Access

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Kenneth F Schulz^{1*}, Douglas G Altman² and David Moher³ for the CONSORT Group

1 Family Health International, Research Triangle Park, NC 27709, USA
2 Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, UK
3 Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

✉ author email ✉ corresponding author email

BMC Medicine 2010, 8:18 doi:10.1186/1741-7015-8-18

Published: 24 March 2010

Abstract

The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.

To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also be published in the *Lancet*, *Obstetrics and Gynecology*, *PLoS Medicine*, *Annals of Internal Medicine*, *Open Medicine*, *Journal of Clinical Epidemiology*, *BMC Medicine*, and *Trials*.



ELSEVIER

Journal of Clinical Epidemiology 63 (2010) e1–e37

Journal of Clinical Epidemiology

ORIGINAL ARTICLE

CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

David Moher^{a,*}, Sally Hopewell^b, Kenneth F. Schulz^c, Victor Montori^d, Peter C. Gøtzsche^e, P.J. Devereaux^f, Diana Elbourne^g, Matthias Egger^h, Douglas G. Altman^b

^aOttawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada, K1H 8L6
^bCentre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford
^cFamily Health International, Research Triangle Park, NC 27709, USA
^dUK Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA
^eThe Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark
^fMcMaster University Health Sciences Centre, Hamilton, Canada
^gMedical Statistics Unit, London School of Hygiene and Tropical Medicine, London
^hInstitute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland

Accepted 8 February 2010

CONSORT checklist

Section / topic	#	Checklist item
TITLE & ABSTRACT	1a	Identification as a randomised trial in the title
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)
INTRODUCTION		
Background and objectives	2a	Scientific background and explanation of rationale
	2b	Specific objectives or hypotheses
METHODS		
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants	4a	Eligibility criteria for participants
	4b	Settings and locations where the data were collected
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
	6b	Any changes to trial outcomes after the trial commenced, with reasons
Sample size	7a	How sample size was determined
	7b	When applicable, explanation of any interim analyses and stopping guidelines
Randomisation		
Sequence generation	8a	Method used to generate the random allocation sequence
	8b	Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

- 25 items
- Rationale for the items:
 - Necessary to evaluate the study
 - Evidence-based, whenever possible
 - Minimum set of essential items

CONSORT checklist (2)

Major changes in CONSORT 2010

Added 3 new items

Registration, Protocol, Funding

Added several sub-items, e.g.

Any important changes to methods after trial commencement, with a discussion of reasons

Why the trial ended or was stopped


Made some items more specific

e.g. allocation concealment mechanism, blinding

Simplified and clarified the wording throughout

Section / topic	#	Checklist item
TITLE & ABSTRACT	1a	Identification as a randomised trial in the title
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)
INTRODUCTION		
Background and objectives	2a	Scientific background and explanation of rationale
	2b	Specific objectives or hypotheses
METHODS		
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants	4a	Eligibility criteria for participants
	4b	Settings and locations where the data were collected
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
	6b	Any changes to trial outcomes after the trial commenced, with reasons
Sample size	7a	How sample size was determined
	7b	When applicable, explanation of any interim analyses and stopping guidelines
Randomisation		
Sequence generation	8a	Method used to generate the random allocation sequence
	8b	Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

CONSORT flow diagram



Current CONSORT extensions

DESIGNS	Cluster	Non-inferiority/ equivalence	Pragmatic
INTERVENTIONS	Herbal	Non- pharmacological	Acupuncture (STRICTA)
DATA	Harms	Abstracts	Patient- reported outcomes

Full details (pdfs and checklists) on CONSORT website:

<http://www.consort-statement.org/>

STROBE Statement

STrengthening the Reporting of OBservational Studies in Epiemiology



STROBE Statement

Strengthening the reporting of observational studies in epidemiology

u^b

UNIVERSITÄT
BERN

Home

Aims

News

Available checklists

Publications

Translations

Commentaries

Discussion forum

STROBE group

Endorsement

Contact

Links

Member login / logout

What is STROBE?

STROBE stands for an international, collaborative initiative of epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct and dissemination of observational studies, with the common aim of **STrengthening the Reporting of OBservational studies in Epidemiology**.

The STROBE Statement is being endorsed by a growing number of biomedical journals. Click [here](#) for full list.

For STROBE-related entries in PubMed click [here](#).

What's new in the STROBE Initiative?

29.08.2013

PLOS Collection: Reporting Guidelines Collection

PLOS journals launches an open access collection of reporting guidelines, commentaries, and related research on guidelines from across PLOS journals. This Collection coincides with the Seventh International Congress on Peer... [\[more\]](#)

[\[more\]](#)



STROBE Statement

- **Guidance on how to report observational studies well (which is rare!)**
 - Focus on 3 main study designs: cohort, case-control, cross-sectional studies
- **Published in Oct 2007: short paper and E&E**
- **Adopted by many journals**

Find it on:

www.equator-network.org

www.strobe-statement.org



STROBE

- **Checklist with 22 items**

- Heading (where in paper), item No
- Recommendation, divided into:
cohort, case-control, cross-sectional study - where different

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants

Three STROBE extensions (1)

- **STREGA (2009)**

- reporting of genetic association studies

Table 1. STREGA Reporting Recommendations, Extended from STROBE Statement

Item	Item Number	STROBE Guideline	Extension for Genetic Association Studies (STREGA)
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract. (b) Provide in the abstract an informative and balanced summary of what was done and what was found.	
Introduction			
<i>Background rationale</i>	2	Explain the scientific background and rationale for the investigation being reported.	
<i>Objectives</i>	3	State specific objectives, including any pre-specified hypotheses.	<i>State if the study is the first report of a genetic association, a replication effort, or both.</i>
Methods			
<i>Study design</i>	4	Present key elements of study design early in the paper.	
<i>Setting</i>	5	Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	
<i>Participants</i>	6	(a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants.	<i>Give information on the criteria and methods for selection of subsets of participants from a larger study, when relevant.</i>
		(b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposed. Case-control study – For matched studies, give matching criteria and the number of controls per case.	
<i>Variables</i>	7	(a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	<i>(b) Clearly define genetic exposures (genetic variants) using a widely-used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin).</i>

Three STROBE extensions (2)

- **STROBE – ME (Oct 2011)**
 - Reporting molecular epidemiology (biomarker studies)

Table 1. The Strengthening the Reporting Observational studies in Epidemiology – Molecular Epidemiology (STROBE-ME) Reporting Recommendations: Extended from STROBE statement.

Item	Item number	STROBE Guidelines	Extension for Molecular Epidemiology Studies (STROBE-ME)
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	ME-1 State the use of specific biomarker(s) in the title and/or in the abstract if they contribute substantially to the findings
Introduction			
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	ME-2 Explain in the scientific background of the study how/why the specific biomarker(s) have been chosen, potentially among many others (e.g., others are studied but reported elsewhere, or not studied at all)
Objectives	3	State specific objectives, including any pre-specified hypotheses	ME-3 A <i>priori</i> hypothesis: if one or more biomarkers are used as proxy measures, state the <i>a priori</i> hypothesis on the expected values of the biomarker(s)
Methods			
Study design	4	Present key elements of study design early in the paper	ME-4 Describe the special study designs for molecular epidemiology (in particular nested case/control and case/cohort) and how they were implemented
<i>Biological sample collection</i>			ME-4.1 Report on the setting of the biological sample collection; amount of sample; nature of collecting procedures; participant conditions; time between sample collection and relevant clinical or physiological endpoints.

Three STROBE extensions (3)

- **STROBE abstract**
 - Reporting observational studies in conference abstracts (online draft)

Item	Recommendation
Title	Indicate the study's design with a commonly used term in the title (e.g cohort, case-control, cross sectional)
Authors	Contact details for the corresponding author
Study design	Description of the study design (e.g cohort, case-control, cross sectional)
Objective	Specific objectives or hypothesis
Methods	
Setting	Description of setting, follow-up dates or dates at which the outcome events occurred or at which the outcomes were present, as well as any points or ranges on other time scales for the outcomes (e.g., prevalence at age 18, 1998-2007).
Participants	<p><i>Cohort study</i>—Give the most important eligibility criteria, and the most important sources and methods of selection of participants. Describe briefly the methods of follow-up</p> <p><i>Case-control study</i>—Give the major eligibility criteria, and the major sources and methods of case ascertainment and control selection</p> <p><i>Cross-sectional study</i>—Give the eligibility criteria, and the major sources and methods of selection of participants</p> <p><i>Cohort study</i>—For matched studies, give matching and number of exposed and unexposed</p> <p><i>Case-control study</i>—For matched studies, give matching criteria and the number of controls per case</p>
Variables	Clearly define primary outcome for this report.
Statistical methods	Describe statistical methods, including those used to control for confounding
Results	
Participants	Report Number of participants at the beginning and end of the study
Main results	<p>Report estimates of associations. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p> <p>Report appropriate measures of variability and uncertainty (e.g., odds ratios with confidence intervals)</p>
Conclusions	General interpretation of study results

E & E papers

- Both guidelines have Explanation and Elaboration papers
- Both can be accessed through their websites or on EQUATOR website – full record

Search for reporting guidelines

Use your browser's Back button to return to your search results



CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Full bibliographic reference

Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.

Ann Int Med. 2010;152(11):726-32. PMID: [20335313](#)

BMC Medicine. 2010;8:18. PMID: [20334633](#)

BMJ. 2010;340:c332. PMID: [20332509](#)

J Clin Epidemiol. 2010;63(8): 834-40. PMID: [20346629](#)

Lancet. 2010;375(9721):1136 [supplementary webappendix](#)

Obstet Gynecol. 2010;115(5):1063-70. PMID: [20410783](#)

Open Med. 2010;4(1):60-68.

PLoS Med. 2010;7(3): e1000251. PMID: [20352064](#)

Trials. 2010;11:32. PMID: [20334632](#)

Language

English

Relevant URLs (full-text if available)

Full-text PDF documents of the CONSORT 2010 Statement, CONSORT 2010 checklist, CONSORT 2010 flow diagram and the CONSORT 2010 Explanation and Elaboration document are available from: <http://www.consort-statement.org/resources/downloads/>

Explanation and elaboration papers

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, for the CONSORT Group. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial.

BMJ. 2010;340:c869. PMID: [20332511](#)

J Clin Epidemiol. 2010;63(8): e1-e37. PMID: [20346624](#)

Previous versions of this guideline / Guideline history

CONSORT 2001



Key reporting guidelines

[CONSORT](#) [Full Record](#) | [Checklist](#) | [Flow Diagram](#)

[STROBE](#) [Full Record](#) | [Checklist](#)

[PRISMA](#) [Full Record](#) | [Checklist](#) | [Flow Diagram](#)

[STARD](#) [Full Record](#) | [Checklist](#) | [Flow Diagram](#)

[COREQ](#) [Full Record](#)

[ENTREQ](#) [Full Record](#)

[SQUIRE](#) [Full Record](#) | [Checklist](#)

[CHEERS](#) [Full Record](#) | [Checklist](#)

[CARE](#) [Full Record](#) | [Checklist](#)

[SAMPL](#) [Full Record](#)

Translations

Some reporting guidelines are also available in languages other than English. Find out more in our [Translations section](#).

About the Library

For information about Library scope and content, identification of reporting guidelines and inclusion/exclusion criteria please visit [About the Library](#).

Visit our [Help page](#) for information about searching for reporting guidelines and for general information about using our website.

Our full catalogue of reporting guidelines is available to download as a PDF: [Reporting Guideline Catalogue August 2013](#).

Library index